The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

As per The Business Research Company’s Metastatic Melanoma Therapeutics Global Market Report 2023, the metastatic melanoma therapeutics market is expected to show significant growth in the forecast period.

Key insights from the metastatic melanoma therapeutics market forecast include:

1. Market Size
   The global metastatic melanoma therapeutics market is expected to grow from $6.41 billion in 2022 to $7.27 billion in 2023 at a compound annual growth rate (CAGR) of 13.4%. The size of metastatic melanoma therapeutics market is expected to reach $11.49 billion in 2027 at a CAGR of 12.1%.

2. Major Driver
   The rising incidence of melanoma cases is expected to propel the growth of the metastatic melanoma therapeutics market going forward. For instance, in January 2023, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, there will be 58,120 new cases of melanomas diagnosed in males and 39,490 in women in the US in 2023, totaling roughly 97,610, and melanoma deaths are predicted to total around 7,990. Furthermore, in March 2022, according to the International Agency for Research on Cancer (IARC), a France-based intergovernmental agency, between 2020 and 2040, there will be a more than 50% increase in cutaneous melanoma cases. In 2020, 325,000 new melanoma cases were predicted to be discovered worldwide, with 57,000 people dying due to the disease. Therefore, the rising incidence of melanoma is driving the growth of the metastatic melanoma therapeutics market.

View More On The Metastatic Melanoma Therapeutics Market Report 2023 – https://www.thebusinessresearchcompany.com/report/metastatic-melanoma-therapeutics-global-market-report

3. Key Trend
   Product innovations are a key trend gaining popularity in the metastatic melanoma therapeutics market. Companies operating in the metastatic melanoma therapeutics market are adopting recent technologies to sustain their position in the market. For instance, in January 2022, Immunocore, a UK-based biotechnology company, announced FDA (Foods and Drugs Association) approval of KIMMTRAK (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma. KIMMTRAK is the first and only FDA-approved T cell receptor (TCR) therapy. This is the first compound created using the ImmTAC technology platform by Immunocore, intended to reroute and activate T lymphocytes to identify and eliminate tumor cells. It showed a statistically and clinically significant overall survival (OS) advantage, with a hazard ratio of 0.51 and a median overall survival (OS) of almost 22 months.

4. Largest Region
   North America was the largest region in the metastatic melanoma therapeutics market in 2022.

5. Major Players
   Major players in the metastatic melanoma therapeutics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Ltd., Eisai Co. Ltd., Incyte Corporation, Exelixis Inc., BeiGene Ltd, Immunocore Holdings plc, Genentech Inc., Iovance Biotherapeutics Inc., Nektar Therapeutics, Adaptimmune Therapeutics plc, AIVITA Biomedical Inc., Idera Pharmaceuticals Inc., Evaxion Biotech A/S, AB Science, AgonOX Inc., InxMed Co. Ltd., NewLink Genetics Corporation, and Vical Inc.

Request A Sample Of The Global Metastatic Melanoma Therapeutics Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12065&type=smp

Key Metastatic Melanoma Therapeutics Market Segments
The global metastatic melanoma therapeutics market is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery
2) By Stages: Stage 0, Stage I, Stage II, Stage III, Stage IV
3) By End User: Hospitals, Specialty Clinics, Home Healthcare, Other End-users

The Metastatic Melanoma Therapeutics Global Market Report 2023  provides an in-depth analysis on the metastatic melanoma therapeutics market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the metastatic melanoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
Melanoma Therapeutics Global Market Report 2023
Melanoma Drugs Global Market Report 2023
Metastatic Breast Cancer Treatment Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model